Non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) are now epidemic in the US population, with up to 30% of adults afflicted with NAFLD and more than 6% with NASH. NASH is a prominent driver of cirrhosis and hepatocellular carcinoma and is now surpassing hepatitis C virus infection as the leading cause of liver transplantation. Obesity is one of the most significant risk factors for developing NASH; in obese individuals, NAFLD is present in up to 90% and NASH is present in up to 55%. At this session, an expert panel will explore NAFLD/NASH pathogenesis and the intrinsic relationship with obesity, emerging evidence of histologic improvements in NAFLD/NASH following weight loss in obese patients, and potential impact of new data on patient management. Come to this free preconference session to improve your competence at applying current and emerging strategies in the diagnosis and treatment of patients with obesity and NAFLD/NASH.
This event is an official TOS Annual Meeting Preconference presented at ObesityWeek 2019. The event is free, but you must register in advance through ObesityWeek registration. Space is limited.
Lunch is not provided, but attendees are welcome to bring lunch to the session. There are grab-and-go restaurants on the first floor of the convention center.
In support of improving patient care, Clinical Care Options is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
In accordance with ACCME requirements, activities are certified for credit through CCO. This activity will be certified by CCO for AMA PRA Category 1 Credit™.
NAFLD/NASH Epidemiology, Burden of Disease in Obese Patients
Overview of NAFLD/NASH Pathogenesis
NASH Interventions - Current
NASH Therapies - Investigational